Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2016-02-02

Clinical Trial Update: Pharmacology-driven Dosing of Fluoropyrimidines in Cancer Patients [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial exploring pharmacology-driven dosing of fluoropyrimidines in colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • 5-Fluorouracil (5-FU)
  • Capecitabine (capecitabine)

Snippet

Sponsor: Cantonal Hospital of St. Gallen | Conditions: Colorectal Cancer | Phase 4 | Status: COMPLETED